Q-omics provides the consensus-scored SNORD114-3 profile across patient tissues and cancer cell-line models. SNORD114-3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SNORD114-3 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, SNORD114-3 RNA expression shows 11,603 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, UCEC, and THYM as cancer lineages where SNORD114-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD114-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD114-3 survival associations across molecular data types. SNORD114-3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD114-3 RNA expression–survival associations across cancer types. High SNORD114-3 expression shows unfavorable associations in THCA, HNSC, ACC, BLCA and KIRP, but favorable associations in LAML. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for SNORD114-3 RNA expression.
This table summarizes SNORD114-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD114-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD114-3 shows lower tumor expression in UCEC, BRCA, BLCA and LUSC. The UCEC box plot shows higher SNORD114-3 RNA expression in normal versus tumor tissue (log2 FC = −0.561, t-test p = .004).
This table shows molecular features associated with SNORD114-3 in patient tissues and cancer cell lines. In patient samples, SNORD114-3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
